NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Total Assets Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual total assets in 2023 was 13.23 Million CAD , down -44.56% from previous year.
NervGen Pharma Corp.'s latest quarterly total assets in 2024 Q2 was 27.88 Million CAD , down -12.26% from previous quarter.
NervGen Pharma Corp. reported annual total assets of 23.87 Million CAD in 2022, up 33.41% from previous year.
NervGen Pharma Corp. reported annual total assets of 17.89 Million CAD in 2021, up 168.1% from previous year.
NervGen Pharma Corp. reported quarterly total assets of 27.88 Million CAD for 2024 Q2, down -12.26% from previous quarter.
NervGen Pharma Corp. reported quarterly total assets of 13.23 Million CAD for 2023 FY, down -44.56% from previous quarter.

Annual Total Assets Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Total Assets of NervGen Pharma Corp. (2023 - 2017)

Year	Total Assets	Total Assets Growth
2023	13.23 Million CAD	-44.56%
2022	23.87 Million CAD	33.41%
2021	17.89 Million CAD	168.1%
2020	6.67 Million CAD	-1.33%
2019	6.76 Million CAD	118.43%
2018	3.09 Million CAD	3620.63%
2017	83.24 Thousand CAD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	31.78 Million CAD	140.14%
2024 Q2	27.88 Million CAD	-12.26%
2023 FY	13.23 Million CAD	-44.56%
2023 Q3	16.35 Million CAD	-6.06%
2023 Q1	19.09 Million CAD	-20.0%
2023 Q2	17.41 Million CAD	-8.81%
2023 Q4	13.23 Million CAD	-19.09%
2022 Q1	13.89 Million CAD	-22.36%
2022 FY	23.87 Million CAD	33.41%
2022 Q2	12.98 Million CAD	-6.56%
2022 Q4	23.87 Million CAD	-17.34%
2022 Q3	28.88 Million CAD	122.45%
2021 Q1	6.3 Million CAD	-5.5%
2021 FY	17.89 Million CAD	168.1%
2021 Q4	17.89 Million CAD	90.83%
2021 Q3	9.37 Million CAD	7.87%
2021 Q2	8.69 Million CAD	37.82%
2020 FY	6.67 Million CAD	-1.33%
2020 Q2	6.12 Million CAD	12.93%
2020 Q4	6.67 Million CAD	-34.87%
2020 Q3	10.24 Million CAD	67.24%
2020 Q1	5.42 Million CAD	-19.79%
2019 Q1	9.75 Million CAD	215.01%
2019 FY	6.76 Million CAD	118.43%
2019 Q4	6.76 Million CAD	-4.17%
2019 Q3	7.06 Million CAD	-21.08%
2019 Q2	8.94 Million CAD	-8.31%
2018 FY	3.09 Million CAD	3620.63%
2018 Q4	3.09 Million CAD	0.0%
2017 FY	83.24 Thousand CAD	0.0%

Peer Total Assets Comparison of NervGen Pharma Corp.

Name	Total Assets	Total Assets Difference
Arch Biopartners Inc.	1.17 Million CAD	-1030.152%
Covalon Technologies Ltd.	24.9 Million CAD	46.845%
Hemostemix Inc.	313.76 Thousand CAD	-4118.45%
Universal Ibogaine Inc.	6.31 Million CAD	-109.51%
Kane Biotech Inc.	5.68 Million CAD	-132.991%
MedMira Inc.	3.65 Million CAD	-262.452%
Marvel Biosciences Corp.	672.38 Thousand CAD	-1868.506%
XORTX Therapeutics Inc.	7.21 Million CAD	-83.577%